Narrative Update: Ryman Healthcare
Analysts have raised their fair value estimate for Ryman Healthcare from $2.98 to $3.07. This change reflects modest upward revisions to forecasts and is supported by slight improvements in the profit margin outlook.
Valuation Changes
- Fair Value Estimate has risen slightly from NZ$2.98 to NZ$3.07.
- Discount Rate has edged up marginally, from 6.96% to 6.98%.
- Revenue Growth expectation has decreased very slightly from 7.43% to 7.42%.
- Net Profit Margin forecast has improved minimally, from 42.30% to 42.31%.
- Future Price/Earnings Ratio is expected to rise from 11.38x to 11.72x.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.